Hemorrhage

8
Pipeline Programs
10
Companies
14
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
6
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
5100%
+ 9 programs with unclassified modality

On Market (1)

Approved therapies currently available

Boehringer Ingelheim
PRAXBINDApproved
idarucizumab
Boehringer Ingelheim
Humanized Monoclonal Antibody Fragment [EPC]injection2015

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
7 programs
1
4
1
IdarucizumabPhase 3Monoclonal Antibody1 trial
IdarucizumabPhase 3Monoclonal Antibody1 trial
idarucizumabPhase 3Monoclonal Antibody1 trial
idarucizumabPhase 3Monoclonal Antibody1 trial
BI 655075Phase 11 trial
+2 more programs
Active Trials
NCT02946931Completed1,402Est. Nov 2020
NCT02798107Withdrawn0Est. May 2019
NCT01955720Completed46Est. Aug 2014
+4 more trials
Corza Medical
Corza MedicalChina - Shanghai
1 program
1
TachoSilPhase 31 trial
Active Trials
NCT06664775RecruitingEst. Jun 2026
Takeda
TakedaTOKYO, Japan
1 program
1
TachoSil®Phase 31 trial
Active Trials
NCT01192022Completed253Est. May 2013
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Andexanet alfaN/A1 trial
Active Trials
NCT05898412Completed217Est. Nov 2025
Merit Medical
Merit MedicalSOUTH JORDAN, UT
1 program
EmboCube Embolization GelatinN/A1 trial
Active Trials
NCT05307783Completed101Est. Apr 2024
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Infrahepatic inferior vena cava clampingN/A1 trial
Active Trials
NCT00732979Completed152Est. Dec 2011
CSL Behring
CSL BehringIL - Bradley
1 program
Kcentra®N/A1 trial
Active Trials
NCT02319460Completed2,238Est. Jun 2020
One Biosciences
One BiosciencesFrance - Paris
1 program
Zhi Byed 11N/A1 trial
Active Trials
NCT00147420CompletedEst. Mar 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Corza MedicalTachoSil
Boehringer IngelheimIdarucizumab
Boehringer IngelheimIdarucizumab
Boehringer Ingelheimidarucizumab
Boehringer Ingelheimidarucizumab
TakedaTachoSil®
Boehringer IngelheimBI 655075
AstraZenecaAndexanet alfa
Merit MedicalEmboCube Embolization Gelatin
Boehringer Ingelheimidarucizumab
Boehringer IngelheimPrizbind®
CSL BehringKcentra®
Heidelberg PharmaInfrahepatic inferior vena cava clamping
One BiosciencesZhi Byed 11

Clinical Trials (14)

Total enrollment: 4,933 patients across 14 trials

NCT06664775Corza MedicalTachoSil

A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery

Start: Apr 2025Est. completion: Jun 2026
Phase 3Recruiting
NCT03343704Boehringer IngelheimIdarucizumab

This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding

Start: Mar 2018Est. completion: Jul 202019 patients
Phase 3Completed
NCT02815670Boehringer IngelheimIdarucizumab

Reversal Dabigatran Anticoagulant Effect With Idarucizumab

Start: Sep 2016Est. completion: Oct 20191 patients
Phase 3Completed
NCT02831660Boehringer Ingelheimidarucizumab

CU Programme of Idarucizumab for Japanese Patients

Start: Jul 2016Est. completion: Sep 20161 patients
Phase 3Completed
NCT02104947Boehringer Ingelheimidarucizumab

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

Start: May 2014Est. completion: Oct 2016503 patients
Phase 3Completed
NCT01192022TakedaTachoSil®

TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

Start: Aug 2010Est. completion: May 2013253 patients
Phase 3Completed
NCT01955720Boehringer IngelheimBI 655075

Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Start: Sep 2013Est. completion: Aug 201446 patients
Phase 1Completed
NCT05898412AstraZenecaAndexanet alfa

Retrospective Study on Characteristics and Outcomes in Hospitalised Patients Treated With Ondexxya

Start: Oct 2023Est. completion: Nov 2025217 patients
N/ACompleted
NCT05307783Merit MedicalEmboCube Embolization Gelatin

EmboCube Gelatin Embolization to Control Bleeding or Hemorrhaging

Start: Nov 2022Est. completion: Apr 2024101 patients
N/ACompleted
NCT02798107Boehringer Ingelheimidarucizumab

Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients

Start: May 2019Est. completion: May 20190
N/AWithdrawn
NCT02946931Boehringer IngelheimPrizbind®

All-Case Surveillance of Prizbind®

Start: Nov 2016Est. completion: Nov 20201,402 patients
N/ACompleted
NCT02319460CSL BehringKcentra®

An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding

Start: Apr 2014Est. completion: Jun 20202,238 patients
N/ACompleted
NCT00732979Heidelberg PharmaInfrahepatic inferior vena cava clamping

Infrahepatic Inferior Vena Cava Clamping During Hepatectomy

Start: Mar 2008Est. completion: Dec 2011152 patients
N/ACompleted
NCT00147420One BiosciencesZhi Byed 11

RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet

Start: Sep 2005Est. completion: Mar 2007
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 4,933 patients
10 companies competing in this space